

个人简历

余华 副教授

地址： 澳门大学北 22 座科研大楼 8008 室 中华医药研究院
中国澳门氹仔 大学大马路

电话： +853-8822 8540

手机： 18165595578

E-mail: bcalecyu@um.edu.mo, yuhuayu@vip.sina.com

个人主页: <https://sklmqcm.um.edu.mo/hua-yu/>

Google Scholar: <https://scholar.google.com/citations?user=ItpPwRYAAAAJ&hl=en>



主要研究领域

主要致力于中药质量的安全性、有效性、稳定性和可控性评价的关键技术研究。研究方向包括：中药学（中药(材)质量一致性评价；中药质量标准研究）；药物制剂（创新剂型的设计与开发；功能性药物载体材料的开发）。

教育

2004.09-2008.07	澳门大学 中华医药研究院	生物医药	博士
2002.09-2004.07	澳门大学 中华医药研究院	中药学	硕士
2001.09-2004.07	中国药科大学 中药学院	生药学	硕士
1995.09-1999.07	中国药科大学 药学院	药物制剂	学士

工作简历

2022.08 – 至今	澳门大学 中华医药研究院	副教授
2015.10 – 2022.08	澳门大学 中华医药研究院	助理教授
2015.03 – 2018.12	香港浸会大学 中医药学院	客座学者
2011.11 – 2018.12	香港浸会大学深圳研究院	副研究员
2015.03 – 2015.10	澳门大学 中华医药研究院	博士后研究员

2011.11 – 2015.02	香港浸会大学 中医药学院	副研究员
2010.01 – 2012.12	福建省中医药研究院	副研究员
2009.10 – 2011.10	香港中文大学 中药研究所	副研究员
2008.10 – 2009.10	香港科技大学 生物化学系	访问学者
2004.10 – 2008.10	香港科技大学 生物化学系	研究助理
1999.08 – 2001.08	浙江金华康恩贝生物制药有限公司	项目主管

承担基金课题

起止年月	项目名称	基金类别	批准号	负责或参与
2025.07-2027.07	芩玄解毒口服液治疗常见上呼吸道感染的人群扩展应用基础研究	澳门科技发展基金	FDCT 0212/2024/AGJ	主持
2025.01-2026.12	稀莪草活性组分及其纳米乳胶治疗皮肤炎症性增生的研究	澳门大学研究基金	MYRG- GRG2024-00240- ICMS-UMDF	主持
2024.01-2025.12	基于多学科方法的中药质量标准研究	澳门大学研究基金	MYRG- GRG2023-00214- ICMS-UMDF	主持
2023.01-2024.12	多基原中药柴胡的质量一致性评价研究	澳门大学研究基金	MYRG2022- 00189-ICMS	主持
2021.06-2024.06	中药九里香多基原植物的再评价及质量标准研究	澳门科技发展基金	FDCT 0159/2020/A3	主持
2021.03-2023.03	神经退行性疾病药物的研发与产业化	澳门科技发展基金	FDCT 0058/2020/AGJ	主持
2019.09-2022.09	基于网络药理学对中药稀莪草新型倍半萜活性成分 Leocarpinolide B 治疗类风湿性关节炎的分子机制及生物药剂学评价	澳门科技发展基金	FDCT 0096/2019/A2	主持
2019.01-2021.12	“Multi-units”-for-“Multi-therapies” strategy for management of ulcerative colitis: Innovative pharmaceutical design based on clinical therapies of traditional Chinese medicine	澳门大学研究基金	MYRG2018- 00043-ICMS	主持
2018.01-2020.12	Development of novel polymeric-nanoparticle for oral delivery of anti-diabetic nephropathy alkaloids isolated from Traditional Chinese Medicine Coptidis Rhizoma	澳门大学研究基金	MYRG2017- 00178-ICMS	主持
2019.07-2021.07	Investigating the use of a naturally occurring anti-inflammatory herbal,	香港卫生署医疗卫生研究基金	16171711	主持(澳门方)

2018.04-2020.03	siegesbeckia herba in minimising postoperative cognitive dysfunction 普瑞巴林创新剂型处方工艺开发与质量标准研究	广州市 2018 年科技创新发展专项资金项目	EF007/ICMS-YH/2018/GSTIC (澳门批准号)	主持(澳门方)
2015.01-2018.12	3 种不同基源豨薟作同一药材使用合理性的再评价	国家自然科学基金 (面上项目)	81470170	主持

主要研究论文(*为通讯作者, **为并列第一作者)

发表研究论文 130+余篇, 近 5 (2020-2025) 年内发表的论文包括:

1. Zhang CH (†), Yao YW (†), Xu WQ, Zhou JY, **Yu H** (*), Li Y (*), Xiong W (*). Arginase-1 responsive lipid nanoparticles for cytosolic TNF- α -siRNA release to alleviate colitis. *Chem Eng J.* 2025, 522: 168039. doi: 10.1016/j.cej.2025.168039.
2. Zheng W, Chen J, Liu J, Han X, Zhang S, Yang C, **Yu H**, Tan W, Zhong Z. Unveiling the potential of natural TLR modulators in cancer immunotherapy. *Pharmacol Res.* 2025 Sep 24;221:107969. doi: 10.1016/j.phrs.2025.107969.
3. Zhao M, Xiao L, Chen Q, Shen L, Zhao G, Linghu K, Ma Q, Dar P, **Yu H** (*). Bioactive Equivalent Combinatorial Compounds contributing to the holistic effect of traditional Chinese medicine Bupleuri chinense DC. *J Ethnopharmacol.* 2025 Jun 26;350:120003. doi: 10.1016/j.jep.2025.120003. Epub 2025 May 26. PMID: 40436123.
4. Liang Y, Miao Z, Chen J, Tan L, Zhao Y, Cui X, Zhong J, Zhong R, Yue W, Qiu B, **Yu H**, He C. Glycine tabacina extract alleviates inflammatory bowel disease via NF- κ B, JNK and Nrf2 signaling pathways. *J Ethnopharmacol.* 2025 May 12;347:119744. doi: 10.1016/j.jep.2025.119744. Epub 2025 Apr 6. PMID: 40199409.
5. Ma QS (†), Chen QL (†), Wu GP, Yao YW, Fan YX, Linghu KG, Chen JM, Xiong W (*), **Yu H** (*). *Siegesbeckia pubescens* makino alleviates ulcerative colitis in mice by modulating the Nrf2/Keap1 pathway. *Front Pharmacol.* 2025 Apr 28;16:1588525. doi: 10.3389/fphar.2025.1588525. PMID: 40356967; PMCID: PMC12066544.
6. Lui BW, Wan BJ, Zhao XY, Zhao YH, Yu **H**, Jiang XH, Zheng YR, Xu Y. The Extract of *Siegesbeckia orientalis* L. Reverses Pro-inflammatory Status of Microglia for Neuroprotection Following Ischemic Stroke in Mice. *Curr Neuropharmacol.* 2025 Apr 25. doi: 10.2174/011570159X349127241214045611. Epub ahead of print. PMID: 40289983.
7. Yao Y (†), Wang J (†), Zhang G, Li Z, **Yu H**, Zhao J, Huang M, Yao C (*), Wang Y (*), Luo H (*). Exploring the quality marker of *Curcuma kwangsiensis* radix from different production regions using the spectrum-effect relationship, serum metabolism, and molecular docking integrated with chemometrics. *J Ethnopharmacol.* 2025 Apr 25;346:119652. doi: 10.1016/j.jep.2025.119652. Epub 2025 Mar 19. PMID: 40118195.
8. Chen J, Quan X, Li Y, Chen J, Hu J, Zhou M, Chen Y, Chen J, Wu C, **Yu H**, Zhao Y (*). *Siegesbeckia orientalis* ethanol extract impedes RAGE-CD11b interaction driven by HMGB1 to alleviate neutrophil-involved neuronal injury poststroke. *Phytomedicine.* 2025 Feb 17;139:156541. doi: 10.1016/j.phymed.2025.156541.

9. Gao Y, Xu T, Wang Y, Hu Y, Yin S, Qin Z (*), **Yu H** (*). Pathophysiology and Treatment of Psoriasis: From Clinical Practice to Basic Research. *Pharmaceutics*. 2025 Jan 3;17(1):56. doi: 10.3390/pharmaceutics17010056.
10. Wang J, Lv X, Li Y, Wu H, Chen M, **Yu H**, Wu J, Li C (*), Xiong W (*). A ROS-responsive hydrogel that targets inflamed mucosa to relieve ulcerative colitis by reversing intestinal mucosal barrier loss. *J Control Release*. 2025 Jan 10;377:606-618. doi: 10.1016/j.jconrel.2024.11.065.
11. Zhang G, Yao Y, Zhang Z, Xiao J, **Yu H**, Zhao J, Yao C (*), Wang Y (*), Luo H (*). Regulation of NLRP3 inflammasome and Caspase-3/4/11 by 2',4'-dihydroxychalcone contributes to anti-colorectal cancer. *Phytomedicine*. 2024 Dec;135:156194. doi: 10.1016/j.phymed.2024.156194.
12. Linghu KG, Tuo YT, Cui WQ, Li TQ, Wang DS, Zhang YY, Zhang J, Zhang T, Wang YE, **Yu H** (*), Shen XC (*), Li HY (*). Tulipalin A suppressed the pro-inflammatory polarization of M1 macrophage and mitigated the acute lung injury in mice via interference DNA binding activity of NF- κ B. *Eur J Pharmacol*. 2024 Dec 5;984:177034. doi: 10.1016/j.ejphar.2024.177034.
13. Linghu K, Cui W, Li T, Tuo Y, Wang D, Pan H, Zhang T, Lin L, **Yu H**, Hu X (*), Li H (*), Shen X (*). Small molecule α -methylene- γ -butyrolactone, an evolutionarily conserved moiety in sesquiterpene lactones, ameliorates arthritic phenotype via interference DNA binding activity of NF- κ B. *Acta Pharm Sin B*. 2024 Aug;14(8):3561-3575. doi: 10.1016/j.apsb.2024.04.004. Epub 2024 Apr 8.
14. Fan Y, Feng R, Zhang X, Wang ZL, Xiong F, Zhang S, Zhong ZF, **Yu H**, Zhang QW, Zhang Z (*), Wang Y (*), Li G (*). Encoding and display technologies for combinatorial libraries in drug discovery: The coming of age from biology to therapy. *Acta Pharm Sin B*. 2024 Aug;14(8):3362-3384. doi: 10.1016/j.apsb.2024.04.006. Epub 2024 Apr 10.
15. Zhong Y, Zhang X, Feng R, Fan Y, Zhang Z (*), Zhang QW, Wan JB, Wang Y (*), **Yu H** (*), Li G (*). OGG1: An emerging multifunctional therapeutic target for the treatment of diseases caused by oxidative DNA damage. *Med Res Rev*. 2024 Nov;44(6):2825-2848. doi: 10.1002/med.22068.
16. Xiao L, Zhao M, Linghu KG, Wu G, Zhang T, Chen C, Guan J, Cao Z, Hu Y, **Yu H** (*). Ganweikang extract protects hepatocytes from oxidative injury by activating Nrf2/HO-1 and MAPKs pathways. *Fitoterapia*. 2024 Oct;178:106146. doi: 10.1016/j.fitote.2024.106146.
17. Linghu KG(†), Zhang T(†), Zhang GT, Lv P, Zhang WJ, Zhao GD, Xiong SH, Ma QS, Zhao MM, Chen MW, Hu YJ, Zhang CS(*), **Yu H**(*). Small molecule deoxyxyboquinone triggers alkylation and ubiquitination of Keap1 at Cys489 on Kelch domain for Nrf2 activation and inflammatory therapy. *J Pharm Anal*. doi: 10.1016/j.jpha.2023.07.009.
18. Feng R(†), Fan Y(†), Zhang X(†), Chen L, Zhong ZF, Wang Y, **Yu H**(*), Zhang QW(*), Li G(*). A Biomimetic Multifunctional Nanoframework for Symptom Relief and Restorative Treatment of Acute Liver Failure. *ACS Nano*. 2024 Jan 31;18(7):5951-64. doi: 10.1021/acsnano.4c00173.
19. Miao L(†), Zhou C(†), Zhang H, Cheong MS, Tan Y, Wang Y, Zhang X, **Yu H**, Cheang WS(*). Portulaca Oleracea L. (Purslane) Extract Protects Endothelial Function by Reducing Endoplasmic Reticulum Stress and Oxidative Stress through AMPK Activation in Diabetic Obese Mice. *Antioxidants (Basel)*. 2023 Dec 18;12(12):2132. doi: 10.3390/antiox12122132.
20. Zhang DY (†), Cui WQ (†), Hou L, Yang J, Lyu LY, Wang ZY, Linghu KG, He WB, **Yu H**, Hu YJ (*). Expanding potential targets of herbal chemicals by node2vec based on herb-drug interactions. *Chin Med*. 2023 Jun 1;18(1):64. doi: 10.1186/s13020-023-00763-3.

21. Linghu KG (†), Zhao GD (†), Zhang DY, Xiong SH, Wu GP, Shen LY, Cui WQ, Zhang T, Hu YJ, Guo B, Shen XC (*), **Yu H** (*). Leocarpinolide B Attenuates Collagen Type II-Induced Arthritis by Inhibiting DNA Binding Activity of NF-κB. *Molecules*. 2023 May 22;28(10):4241. doi: 10.3390/molecules28104241.
22. Xu JQ, Su SB, Chen CY, Gao J, Cao ZM, Guan JL, Xiao LX, Zhao MM, **Yu H** (*), Hu YJ (*). Mechanisms of Ganweikang Tablets against Chronic Hepatitis B: A Comprehensive Study of Network Analysis, Molecular Docking, and Chemical Profiling. *Biomed Res Int*. 2023 May 8;2023:8782892. doi: 10.1155/2023/8782892.
23. Zhou W, Lei B, Yang C, Silva M, Xing X, **Yu H**, Lu J, Zheng W (*). Artemisia annua Extract Improves the Cognitive Deficits and Reverses the Pathological Changes of Alzheimer's Disease via Regulating YAP Signaling. *Int J Mol Sci*. 2023 Mar 9;24(6):5259. doi: 10.3390/ijms24065259.
24. Li Q, Liu X, Yan C, Zhao B, Zhao Y, Yang L, Shi M, **Yu H** (*), Li X (*), Luo K (*). Polysaccharide-Based Stimulus-Responsive Nanomedicines for Combination Cancer Immunotherapy. *Small*. 2023 Jun;19(23):e2206211. doi: 10.1002/sml.202206211.
25. Sun M, Huang D, Liu Y, Chen H, **Yu H**, Zhang G, Chen Q (*), Chen H (*), Zhang J (*). Effects of Cinobufagin on the Proliferation, Migration, and Invasion of H1299 Lung Cancer Cells. *Chem Biodivers*. 2023 Jan;20(1):e202200961. doi: 10.1002/cbdv.202200961.
26. Zhang L (†), **Yu H** (†), Chen H, Huang Y, Bakunina I, de Sousa DP (*), Sun M (*), Zhang J (*). Application of molecular imprinting polymers in separation of active compounds from plants. *Fitoterapia*. 2023 Jan;164:105383. doi: 10.1016/j.fitote.2022.105383.
27. Zhong W (†), Guo F (†), Chen F, Law MK, Lu J, Shao D, **Yu H**, Chan G, Chen M (*). A multifunctional oxidative stress nanoamplifier with ROS amplification and GSH exhaustion for enhanced chemodynamic therapy. *Front Pharmacol*. 2022 Nov 10;13:1044083. doi: 10.3389/fphar.2022.1044083.
28. Zhao M (†), Xiao L (†), Linghu KG, Zhao G, Chen Q, Shen L, Dar P, Chen M, Hu Y, Zhang J (*), **Yu H** (*). Comprehensive comparison on the anti-inflammation and GC-MS-based metabolomics discrimination between *Bupleuri chinense* DC. and *B. scorzoniferifolium* Willd. *Front Pharmacol*. 2022 Sep 14;13:1005011. doi: 10.3389/fphar.2022.1005011.
29. Linghu KG (†), Ma Q (†), Xiong SH, Zhao M, Chen Q, Xu W, Chen M, Zhang JY, Hu Y, Xu W (*), **Yu H** (*). The "whole ingredients extract" of *Astragali Radix* improves the symptoms of dextran sulfate sodium-induced ulcerative colitis in mice through systemic immunomodulation. *Chin Med*. 2022 Sep 15;17(1):109. doi: 10.1186/s13020-022-00661-0.
30. Zhao M, Linghu KG, Xiao L, Hua T, Zhao G, Chen Q, Xiong S, Shen L, Yu J, Hou X, Hao E, Du Z, Deng J, Bai G, Chen X, Li L (*), Li P (*), **Yu H** (*). Anti-inflammatory/anti-oxidant properties and the UPLC-QTOF/MS-based metabolomics discrimination of three yellow camellia species. *Food Res Int*. 2022 Oct;160:111628. doi: 10.1016/j.foodres.2022.111628.
31. Chen Y (†), Xiong SH (†), Li F, Kong XJ, Ouyang DF, Zheng Y, **Yu H** (*), Hu YJ (*). Delivery of therapeutic small interfering RNA: The current patent-based landscape. *Mol Ther Nucleic Acids*. 2022 Jun 22;29:150-161. doi: 10.1016/j.omtn.2022.06.011.
32. Tan Y, Zhang X, Zhou Y, Miao L, Xu B, Khan H, Wang Y, **Yu H**, Cheang WS (*). *Panax notoginseng* extract and total saponin suppress diet-induced obesity and endoplasmic reticulum stress in epididymal white adipose tissue in mice. *Chin Med*. 2022 Jun 20;17(1):75. doi: 10.1186/s13020-022-00629-0.

33. Li Z, Li Z, **Yu H**, Wang B, Song W, Liu J (*). Tailoring therapeutic effect for chronotherapy of variant angina based on pharmacodynamic/deconvolution integrated model method. *Eur J Pharm Sci.* 2022 Aug 1;175:106208. doi: 10.1016/j.ejps.2022.106208.
34. Deng ZF(†), Bakunina I (†), **Yu H** (†), Han J, Dömling A (*), Ferreira MU (*), Zhang JY(*). Research Progress on Natural Diterpenoids in Reversing Multidrug Resistance. *Front. Pharmacol.* 2022, 13:815603. doi: 10.3389/fphar.2022.815603.
35. Chu JMT (†), Abulimiti A (†), Wong BSH, Zhao GD, Xiong SH, Zhao MM, Wang Y, Chen Y, Wang AJ, Zhang Y, Chang RCC, **Yu H** (*), Wong GTC (*). *Sigesbeckia orientalis* L. derived active fraction ameliorated perioperative neurocognitive disorder through alleviating hippocampal neuroinflammation. *Front. Pharmacol.* 2022, 13:846631. doi: 10.3389/fphar.2022.846631.
36. Wang Z (†), Wang X (†), **Yu H**, Chen M (*). Glioma-targeted multifunctional nanoparticles to co-deliver camptothecin and curcumin for enhanced chemo-immunotherapy. *Biomater Sci.* 2022 Mar 2;10(5):1292-1303. doi: 10.1039/d1bm01987b.
37. Chen L, Lu J, Luo M, **Yu H**, Chen X, Deng J, Hou X, Hao E, Wei J (*), Li P (*). A ratiometric fluorescent sensing system for the selective and ultrasensitive detection of pesticide residues via the synergetic effects of copper nanoclusters and carbon quantum dots. *Food Chem.* 2022 Jun 15;379:132139. doi: 10.1016/j.foodchem.2022.132139.
38. Yang S, Wong KH, Hua P, He C, **Yu H**, Shao D, Shi Z, Chen M (*). ROS-responsive fluorinated polyethyleneimine vector to co-deliver shMTHFD2 and shGPX4 plasmids induces ferroptosis and apoptosis for cancer therapy. *Acta Biomater.* 2022 Mar 1;140:492-505. doi: 10.1016/j.actbio.2021.11.042.
39. Huo XX (†), Wang SJ (†), Song H, Li MD, **Yu H**, Wang M, Gong HX, Qiu XT, Zhu YF (*), Zhang JY (*). Roles of Major RNA Adenosine Modifications in Head and Neck Squamous Cell Carcinoma. *Front Pharmacol.* 2021 Nov 25;12:779779. doi: 10.3389/fphar.2021.779779.
40. Wang S (†), Cao J (†), Deng J, Hou X, Hao E, Zhang L, **Yu H** (*), Li P (*). Chemical characterization of flavonoids and alkaloids in safflower (*Carthamus tinctorius* L.) by comprehensive two-dimensional hydrophilic interaction chromatography coupled with hybrid linear ion trap Orbitrap mass spectrometry. *Food Chem X.* 2021 Oct 16;12:100143. doi: 10.1016/j.fochx.2021.100143.
41. Zhang X, Zhou C, Miao L, Tan Y, Zhou Y, Cheong MS, Huang Y, Wang Y, **Yu H**, Cheang WS (*). Panax Notoginseng Protects against Diabetes-Associated Endothelial Dysfunction: Comparison between Ethanol Extract and Total Saponin. *Oxid Med Cell Longev.* 2021 Sep 4;2021:4722797. doi: 10.1155/2021/4722797.
42. Gao H (†), Su Y (†), Wang W (†), Xiong W, Sun X, Ji Y, **Yu H** (*), Li H (*), Ouyang D (*). Integrated computer-aided formulation design: A case study of andrographolide/ cyclodextrin ternary formulation. *Asian Journal of Pharmaceutical Sciences.* Accepted 21th March 2021. doi: 10.1016/j.ajps.2021.03.006.
43. Zhang XJ (†), Gao QM (†), Zhuang QF (†), Zhang L (†), Wang SH, Du LB, Yuan WX, Wang CF, Tian Q, **Yu H**, Zhao YM (*), Liu Y. A dual-functional nanovehicle with fluorescent tracking and its targeted killing effects on hepatocellular carcinoma cells. *RSC Adv.* 2021 Mar 16;11(18):10986-10995. doi: 10.1039/d0ra10486h.
44. Luo K (†), Gao Y (†), Yin S, Yao Y, **Yu H** (*), Wang G, Li J (*). Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer. *Acta Biomater.* 2021, Jul 18: S1742-7061(21)00467-0. doi: 10.1016/j.actbio.2021.07.029.

45. Xiong W, Xiong SH, Chen QL, Linghu KG, Zhao GD, Chu JMT, Wong GTC, Li J, Hu YJ, Wang YT, **Yu H** (*). Brij-functionalized chitosan nanocarrier system enhances the intestinal permeability of P-glycoprotein substrate-like drugs. *Carbohydr Polym.* 2021 Aug 15; **266**: 118112. doi: 10.1016/j.carbpol.2021.118112.
46. Yan YY, Guo QR, Wang FH, Adhikari R, Zhu ZY, Zhang HY, Zhou WM, **Yu H** (*), Li JQ (*), Zhang JY (*). Cell-Free DNA: Hope and Potential Application in Cancer. *Front Cell Dev Biol.* 2021 Feb 22; **9**: 639233. doi: 10.3389/fcell.2021.639233.
47. Ma GL, Du X, Zhu JP, Xu F, **Yu H**, Li J (*). Multi-functionalized dendrimers for targeted co-delivery of sorafenib and paclitaxel in liver cancers. *J Drug Deliv Sci Technol.* doi: 10.1016/j.jddst.2021.102493.
48. Luo KP, Lian YF, Zhang M, **Yu H**, Wang GJ, Li J (*). Charge convertible biomimetic micellar nanoparticles for enhanced melanoma-targeted therapy through tumor cells and tumor-associated macrophages dual chemotherapy with IDO immunotherapy. *Chem Eng J.* 2021, **412**: 128659. doi: 10.1016/j.cej.2021.128659.
49. Tao HX, Zhao GD, Linghu KG, Xiong W, Sang W, Peng Y, Wang YT, **Yu H** (*). Botany, traditional use, phytochemistry, pharmacology and toxicology of *Sigesbeckiae Herba* (Xixiancao): a review. *Phytochem Rev.* 2021, **20**: 569-587. doi: 10.1007/s11101-020-09714-4.
50. Luo K (†), Xu F (†), Yao T, Zhu J, **Yu H**, Wang G, Li J (*). TPGS and chondroitin sulfate dual-modified lipid-albumin nanosystem for targeted delivery of chemotherapeutic agent against multidrug-resistant cancer. *Int J Biol Macromol.* 2021 Jul 31; **183**: 1270-1282. doi: 10.1016/j.ijbiomac.2021.05.070.
51. Luo H, Vong CT, Tan D, Zhang J, **Yu H**, Yang L, Zhang C, Luo C, Zhong Z (*), Wang Y (*). Panax notoginseng Saponins Modulate the Inflammatory Response and Improve IBD-Like Symptoms via TLR/NF-[Formula: see text]B and MAPK Signaling Pathways. *Am J Chin Med.* 2021; **49**(4): 925-939. doi: 10.1142/S0192415X21500440.
52. Vong CT, Tseng HHL, Yao P, **Yu H**, Wang S, Zhong Z (*), Wang Y (*). Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases. *Drug Discov Today.* 2021 Jun; **26**(6): 1394-1408. doi: 10.1016/j.drudis.2021.02.018.
53. Zuo HL, Zhang QR, Chen C, Yang FQ, **Yu H** (*), Hu YJ (*). Molecular evidence of herbal formula: a network-based analysis of Si-Wu decoction. *Phytochem Anal.* 2021, **32**(2): 198-205. doi: 10.1002/pca.2965.
54. Luo H (†), Zhao M (†), Tan D (†), Liu C, Yang L, Qiu L, Gao Y, **Yu H** (*). Anti-COVID-19 drug screening: Frontier concepts and core technologies. *Chin Med.* 2020 Oct 28; **15**: 115. doi: 10.1186/s13020-020-00393-z.
55. Linghu KG (†), Xiong SH (†), Zhao GD, Zhang T, Xiong W, Zhao M, Shen XC, Xu W, Bian Z, Wang Y, **Yu H** (*). *Sigesbeckia orientalis* L. Extract Alleviated the Collagen Type II-Induced Arthritis Through Inhibiting Multi-Target-Mediated Synovial Hyperplasia and Inflammation. *Front Pharmacol.* 2020 Aug 28; **11**: 547913. doi: 10.3389/fphar.2020.547913.
56. Luo K, Yin S, Zhang R, **Yu H**, Wang G, Li J (*). Multifunctional composite nanoparticles based on hyaluronic acid-paclitaxel conjugates for enhanced cancer therapy. *Int J Pharm.* 2020 Nov 15; **589**: 119870. doi: 10.1016/j.ijpharm.2020.119870.
57. Ma QS (†), Linghu KG (†), Zhang T, Zhao GD, Xiong W, Xiong SH, Zhao M, Xu W, Yu J, **Yu H** (*). *Sigesbeckia glabrescens* Makino extract attenuated the collagen-induced arthritis through inhibiting the synovial hyperplasia and inflammation. *Chin Med.* 2020 Aug 27; **15**: 91. doi: 10.1186/s13020-020-00372-4.

58. Chen YC, Huang MY, Zhang LL, Feng ZL, Jiang XM, Yuan LW, Huang RY, Liu B, **Yu H**, Wang YT, Chen XP, Lin LG, Lu JJ (*). Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells. *Chin J Nat Med*. 2020 Jul; **18**(7): 517-525. doi: 10.1016/S1875-5364(20)30062-5.
59. Liu K, Zuo H, Li G, **Yu H**, Hu Y (*). Global research on artemisinin and its derivatives: Perspectives from patents. *Pharmacol Res*. 2020 Sep; **159**:105048. doi: 10.1016/j.phrs.2020.105048.
60. Li Q (†), Wang G (†), Xiong SH, Cao Y, Liu B, Sun J, Li L, Mohammadtursun N, **Yu H**, Dong J (*), Wu J (*). Bu-Shen-Fang-Chuan formula attenuates cigarette smoke-induced inflammation by modulating the PI3K/Akt-Nrf2 and NF-κB signalling pathways. *J Ethnopharmacol*. 2020 Oct 28; **261**: 113095. doi: 10.1016/j.jep.2020.113095.
61. Zuo HL, Linghu KG, Wang YL, Liu KM, Gao Y, **Yu H**, Yang FQ (*), Hu YJ (*). Interactions of antithrombotic herbal medicines with Western cardiovascular drugs. *Pharmacol Res*. 2020 Sep; **159**: 104963. doi: 10.1016/j.phrs.2020.104963.
62. Linghu KG (†), Zhao GD (†), Xiong W, Sang W, Xiong SH, Tse AKW, Hu Y, Bian Z, Wang Y, **Yu H** (*). Comprehensive comparison on the anti-inflammatory effects of three species of *Sigesbeckia* plants based on NF-κB and MAPKs signal pathways *in vitro*. *J Ethnopharmacol*. 2020 Mar 25; **250**: 112530. doi: 10.1016/j.jep.2019.112530.
63. Linghu KG, Ma QS, Zhao GD, Xiong W, Lin L, Zhang QW, Bian Z, Wang Y, **Yu H** (*). Leocarpinolide B attenuates LPS-induced inflammation on RAW264.7 macrophages by mediating NF-κB and Nrf2 pathways. *Eur J Pharmacol*. 2020 Feb 5; **868**: 172854. doi: 10.1016/j.ejphar.2019.172854.
64. Du X (†), Yin S (†), Xu L, Ma J, **Yu H**, Wang G, Li J (*). Polylysine and cysteine functionalized chitosan nanoparticle as an efficient platform for oral delivery of paclitaxel. *Carbohydr Polym*. 2020 Feb 1; **229**: 115484. doi: 10.1016/j.carbpol.2019.115484.
65. Gao HS, Ye ZYF, Dong J, Gao HL, **Yu H**, Li HF, Ouyang DF (*). Predicting drug/phospholipid complexation by the lightGBM method. *Chem Phys Lett*. 2020, **747**: 137354. doi: 10.1016/j.cplett.2020.137354.